Targeting Immunosuppressive MARCO+ Myeloid Cells to Unleash Anti-Tumor Immunity

Time: 3:45 pm
day: Day One


  • Pionyr identified the Macrophage Receptor with a Collagenous Structure (MARCO) as a potential myeloid reprogramming target and developing a humanized  anti-MARCO monoclonal antibody (mAb), termed PY265
  • PY265 induced reprogramming of M2-like macrophages and immunosuppressive mMDSCs to M1-like  macrophages and pro-inflammatory monocytes, leading  to pro-inflammatory immune activation
  • PY265m, a surrogate antibody specific to mouse MARCO, demonstrated significant anti-tumor activity both as a single agent in CPI-sensitive syngeneic tumor models and in combination with anti-PD-1 in CPIresistant syngeneic tumor models